Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in this randomized controlled trial publication.

The objective of this article is to assess the effects of sustained CGRP inhibition on blood pressure, heart rate, and ECGs in healthy women ≥ 40 years of age.

Why It Was Studied

The vascular effects of acute calcitonin gene-related peptide (CGRP) inhibition are well described, but the effects of sustained inhibition warrant further exploration in humans.

Who Took Part

The abstract describes 31 women taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, women only.

Participants were confined for seven days and followed for 168 days.

Hemodynamic assessments and ECGs were conducted six times during Day 1 and periodically for three months.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Neither the women nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the CGRP (Calcitonin Gene-Related Peptide) group a baseline to be compared against.

The methods mention a period of 168 days.

Cardiac telemetry was conducted for eight hours after infusion completion.

What Was Measured

The subject headings attached to it are Antibodies, Monoclonal, Blood Pressure, Calcitonin Gene-Related Peptide, Electrocardiography, Enzyme-Linked Immunosorbent Assay and Heart Rate.

Author keywords: CGRP, cardiovascular and monoclonal antibodies.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in 31 women over 168 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Cephalalgia : an international journal of headache), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, all human trials.